Vanda Pharmaceuticals Inc.
VNDAFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Vanda Pharmaceuticals Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 8, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| PANAGORA ASSET MANAGEMENT INC | 2026-03-31 | 113,289 | $783K | SEC filing |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 2026-03-31 | 32,504 | $223K | SEC filing |
| MIRABELLA FINANCIAL SERVICES LLP | 2026-03-31 | 12,616 | $87.2K | SEC filing |
| WINTON GROUP Ltd | 2026-03-31 | 44,800 | $310K | SEC filing |
| Empire Financial Management Company, LLC | 2026-03-31 | 922,245 | $6.37M | SEC filing |
| Sterling Capital Management LLC | 2026-03-31 | 1,846 | $12.8K | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 304,894 | $2.03M | SEC filing |
| SJS Investment Consulting Inc. | 2026-03-31 | 152 | $1.05K | SEC filing |
| Optiver Holding B.V. | 2026-03-31 | 20,336 | $141K | SEC filing |
| Essential Partners LLC | 2026-03-31 | 3,242 | $22.4K | SEC filing |
| FEDERATED HERMES, INC. | 2026-03-31 | 575,389 | $3.98M | SEC filing |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2026-03-31 | 41,820 | Not shown | SEC filing |
| AMERIPRISE FINANCIAL INC | 2026-03-31 | 177,581 | $1.23M | SEC filing |
| JONES FINANCIAL COMPANIES LLLP | 2026-03-31 | 420 | $2.9K | SEC filing |
| STATE OF WISCONSIN INVESTMENT BOARD | 2026-03-31 | 200,463 | $1.39M | SEC filing |
| JANE STREET GROUP, LLC | 2026-03-31 | 210,243 | $1.45M | SEC filing |
| Russell Investments Group, Ltd. | 2026-03-31 | 77,275 | $534K | SEC filing |
| Jump Financial, LLC | 2026-03-31 | 198,867 | $1.37M | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 80,809 | $558K | SEC filing |
| NATIONS FINANCIAL GROUP INC, /IA/ /ADV | 2026-03-31 | 14,000 | $96.7K | SEC filing |
- Each value is checked against Vanda Pharmaceuticals Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Vanda Pharmaceuticals Inc.'s share price.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Vanda Pharmaceuticals Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-03-02 · Polymeropoulos Mihael Hristos: Larger than 86 of the 87 other insider sales of Common Stock on file. SEC filing
- 2026-03-02 · Williams Timothy: Larger than 79 of the 87 other insider sales of Common Stock on file. SEC filing
- 2026-03-02 · Moran Kevin Patrick: Larger than 80 of the 87 other insider sales of Common Stock on file. SEC filing
- 2025-05-16 · Polymeropoulos Mihael Hristos: Larger than all 14 other insider purchases of Common Stock on file. SEC filing
- 2022-12-06 · Polymeropoulos Mihael Hristos: Larger than 83 of the 87 other insider sales of Common Stock on file. SEC filing
- 2022-12-05 · Polymeropoulos Mihael Hristos: Larger than 82 of the 87 other insider sales of Common Stock on file. SEC filing
- 2021-12-01 · Polymeropoulos Mihael Hristos: Larger than 81 of the 87 other insider sales of Common Stock on file. SEC filing
- 2021-11-30 · Polymeropoulos Mihael Hristos: Larger than 84 of the 87 other insider sales of Common Stock on file. SEC filing
- 2021-03-08 · Polymeropoulos Mihael Hristos: Larger than all 87 other insider sales of Common Stock on file. SEC filing
- 2020-12-14 · Polymeropoulos Mihael Hristos: Larger than 85 of the 87 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-03-02 | Moran Kevin Patrick · SVP, CFO & Treasurer | Common Stock | S — Open market or private sale | −42,442 | 8.27 | SEC filing |
| 2026-03-02 | Birznieks Gunther · SVP, Business Development | Common Stock | S — Open market or private sale | −42,431 | 8.27 | SEC filing |
| 2026-03-02 | Williams Timothy · SVP & General Counsel | Common Stock | S — Open market or private sale | −42,434 | 8.27 | SEC filing |
| 2026-03-02 | Wijkstrom Joakim · SVP, Chief Marketing Officer | Common Stock | S — Open market or private sale | −30,800 | 8.27 | SEC filing |
| 2026-03-02 | Polymeropoulos Mihael Hristos · President and CEO | Common Stock | S — Open market or private sale | −156,235 | 8.17 | SEC filing |
| 2026-02-23 | Honore Tage · Director | Common Stock | S — Open market or private sale | −30,000 | 8.03 | SEC filing |
| 2025-08-07 | Polymeropoulos Mihael Hristos · President and CEO | Common Stock | P — Open market or private purchase | +10,000 | 4.15 | SEC filing |
| 2025-06-13 | Mitchell Stephen Ray · Director | Common Stock | S — Open market or private sale | −7,000 | 4.59 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-04 | McGuire Daniel Patrick · SVP, GC and Secretary | Common Stock | A — Grant, award, or other acquisition | +80,000 | SEC filing |
| 2026-06-04 | Duncan Charles Cliff · Director | Common Stock | A — Grant, award, or other acquisition | +41,600 | SEC filing |
| 2026-06-04 | Ward Anne Sempowski · Director | Common Stock | A — Grant, award, or other acquisition | +41,600 | SEC filing |
| 2026-06-04 | Chrousos Phaedra · Director | Common Stock | A — Grant, award, or other acquisition | +41,600 | SEC filing |
| 2026-06-04 | Honore Tage · Director | Common Stock | A — Grant, award, or other acquisition | +41,600 | SEC filing |
| 2026-06-04 | Mitchell Stephen Ray · Director | Common Stock | A — Grant, award, or other acquisition | +41,600 | SEC filing |
| 2026-06-04 | DUGAN RICHARD W · Director | Common Stock | A — Grant, award, or other acquisition | +41,600 | SEC filing |
| 2026-05-18 | Mitchell Stephen Ray · Director | Common Stock | G — Bona fide gift | −25,836 | SEC filing |
Showing 8 of 26 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.